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Background: The incidence of leptomeningeal carcinomatosis (LC) 
has increased in patients with metastatic non–small-cell lung cancer 
(NSCLC) because of recent improvements in survival. The clinical 
features and prognostic factors of LC in NSCLC patients, however, 
have not been well identified. The aim of this study was to identify the 
clinical features and prognostic factors of NSCLC patients with LC.
Methods: One hundred and forty-nine consecutive NSCLC patients 
with cytologically proven LC diagnoses between 2001 and 2009 at 
Samsung Medical Center were retrospectively reviewed.
Results: The median age was 58 years (range, 34–80) with most 
patients (135, 95%) having histology indicating adenocarcinoma. 
Twenty-six patients (17.4%) had LC at the initial presentation of 
lung cancer. Treatment for LC consisted of intrathecal chemother-
apy (ITC) alone in 44 patients, ITC plus systemic therapy in 18 
patients, ITC plus radiotherapy in 29 patients, all three treatments in 
18 patients, and other treatments without ITC in 20 patients. Twenty 
patients received only supportive care. The median follow-up dura-
tion was 34 months and the median overall survival from diagnosis of 
LC was 14 weeks (95% confidence interval [CI] 12, 16). In univari-
ate analysis, encephalopathy, Eastern Cooperative Oncology Group 
(ECOG) performance status, low initial cerebrospinal fluid (CSF) 
glucose, high initial CSF protein, high initial CSF white blood cell 
count, treatment with ITC, systemic therapy with epidermal growth 
factor receptor tyrosine kinase inhibitors or cytotoxic chemotherapy, 
whole-brain radiotherapy (WBRT), ventriculoperitoneal (VP) shunt 
operations, and negative cytologic conversion after ITC were identi-
fied as variables that had prognostic influence on survival. In multi-
variate analysis, poor ECOG performance status (p = 0.026), high 
protein level of CSF (p = 0.027), and high initial CSF WBC count 
(p = 0.015) remained significant predictors of poor prognosis for 
survival, whereas ITC (p < 0.001), EGFR-TKI use (p = 0.018), 
WBRT (p = 0.009), and VP shunt operation (p = 0.013) remained 
significant predictors of favorable prognosis for survival.
Conclusions: Even though the prognosis of LC from NSCLC is poor, 
small subsets of these patients survive longer. Our results suggest that 
more active treatment strategies including ITC, WBRT, and EGFR-
TKI use might improve clinical outcomes in NSCLC patients with LC 
and good performance status, low initial CSF protein and WBC counts.
Key Words: Non–small-cell lung cancer, Leptomeningeal carcino-
matosis, Prognostic factors, Epidermal growth factor receptor tyro-
sine kinase inhibitors.
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Leptomeningeal carcinomatosis (LC) is a rare but rapidly fatal clinical condition occurring in 1% to 5% of all patients with 
solid tumors.1–7 Without therapy, the median survival time is 
only 4 to 6 weeks, but survival can be extended to 4 to 6 months 
with treatment in selected patients.7 Adenocarcinoma is the 
histological indicator most frequently associated with LC, and 
breast cancer, lung cancer, and melanoma are the most common 
primary tumors resulting in LC with rates up to 20%.2,8 Recently, 
the incidence of LC has increased because of new, effective anti-
cancer treatments against primary tumors and improvements in 
neuroimaging techniques.4,9 Prolonged survival has been par-
ticularly evident in certain lung cancer patients with the devel-
opment of epidermal growth factor receptor (EGFR) tyrosine 
kinase inhibitors (TKI) such as gefitinib or erlotinib.
The treatment of LC usually includes intrathecal 
chemotherapy (ITC), systemic therapy, radiotherapy, and 
surgery. Surgery and radiotherapy are mainly reserved for 
the palliation of hydrocephalus or symptoms resulting from 
focal lesions.2–4,9,10 Systemic chemotherapy remains an 
option to treat systemic disease, but data on lone systemic 
chemotherapy in patients with LC are lacking. Although there 
are recent reports on EGFR-TKI use in patients with LC, these 
studies included only a small number of patients.11–13 As for 
ITC, there is no consensus regarding its survival benefit14,15 
because of heterogeneous results from several randomized 
studies on intrathecally applied cytotoxic agents.16–18
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Today, the debate about the optimal treatment for LC 
continues, and no standard guidelines exist. Given that pre-
vious studies of LC included various types of malignancies 
such as breast cancer, lung cancer, melanoma, and other 
hematologic malignancies, the heterogeneity of disease 
makes it difficult to identify prognostic factors associated 
with LC. Accordingly, we were prompted to investigate LC 
solely in patients with non–small-cell lung cancer (NSCLC). 
The purpose of this study was to identify prognostic factors 
associated with LC in NSCLC patients according to clinical 
features, laboratory findings, and treatment modalities, which 
in turn may contribute to evidence-based clinical practice for 
physicians.
PATIENTS AND METHODS
Patients
We retrospectively reviewed 149 NSCLC patients who 
were diagnosed with LC at the Samsung Medical Center in 
Seoul, Korea, between 2001 and 2009. Only patients with LC 
confirmed by cytology were included in this study. According 
to clinical guidelines, CSF exploration was only performed in 
patients who developed neurological problems or had abnor-
mal brain imaging.
Parameters
We evaluated demographic data, clinical features, 
tumor-related features, CSF findings, and treatments. The 
clinical features at LC presentation were classified into five 
groups:19  (1) supratentorial symptoms (seizures, cognitive 
impairment, dysphasia, difficulty in walking, sensory impair-
ment, unexplained weakness, decreased visual acuity), (2) 
infratentorial symptoms (cranial, radicular, or spinal nerve 
involvement), (3) endocranial hypertension, (4) endocranial 
hypertension plus other symptoms, and (5) encephalopathy.
In terms of tumor-related features, the histology, the 
presence or absence of an EGFR gene mutation, and the pres-
ence or absence of concurrent brain metastases at the time of 
LC diagnosis were analyzed. CSF findings that were assessed 
included fluid cytology, opening pressure, glucose concen-
tration, and protein concentration at LC presentation. With 
respect to treatment, we evaluated whether intrathecal chemo-
therapy, systemic chemotherapy, EGFR-TKIs, or radiotherapy 
were used.
Treatment of LC
Management decisions in the treatment of LC were 
made at the treating physician’s discretion. For intrathecal che-
motherapy, methotrexate at a dose of 15 mg twice a week was 
delivered via Ommaya reservoir until the cytology cleared. 
Cytological analysis of CSF was performed just before each 
administration of intrathecal chemotherapy. After cytology 
was deemed clear, patients received intrathecal methotrexate 
once a week for 4 weeks and subsequently once every 2 weeks 
for the next 3 months. Systemic therapy included cytotoxic 
chemotherapy and EGFR-TKIs such as gefitinib or erlotinib. 
Whole-brain radiotherapy was usually performed at a dose of 
30 Gy in five to 10 daily fractions.
Statistical analysis
Overall survival was defined as the period from LC 
diagnosis until death or last follow-up. The date of LC diagno-
sis was defined as the date of the first positive cytologic study. 
Kaplan–Meier estimates were used in the analysis of the time-
to-event variables and 95% confidence intervals (CI) were 
calculated for the median time to event. Survival comparisons 
by univariate analysis were estimated using the log-rank test. 
Cox’s proportional hazard model was used for multivariate 
analyses. A p value of less than 0.05 was considered to be 
statistically significant.
RESULTS
Characteristics of Patients
Demographic and clinical characteristics of the patients 
are summarized in Table 1. The median age at the time of the 
LC diagnosis was 58 years (range, 34–80). All patients were of 
Korean descent and the ratio of men to women was 1.04. A large 
majority of the patients were found to have adenocarcinoma 
histology (95.1%) and most were initially diagnosed with stage 
IV disease (79.9%). Testing for an EGFR gene mutation was 
only performed in 23 patients; 13 of those patients (59.1%) 
were determined to have an activating EGFR gene mutation. 
The EGFR mutations included a deletion mutation in exon 19 
that was found in seven patients, an L858R point mutation in 
exon 21 that was found in five patients, and point mutations 
in exons 18 and 20 that were found in only one patient. One 
of the patients with an L858R point mutation was also found 
to have a point mutation in exon 20. Among 149 LC patients, 
TABLE 1.  Patients’ Characteristics (n = 149)
No. of patients (%)
Median age (yrs) 58 (34–80)
Sex (male: female) 76: 73 (51: 49)
Smoking history (smoker: nonsmoker) 66: 83 (44: 56)
Histology
 Adenocarcinoma
 Nonadenocarcinoma
 Unknown
135 (95.1)
7 (4.9)
7 (4.9)
Initial stage
  I
 II
 III
 IV
6 (4.0)
4 (2.7)
20 (13.4)
119 (79.9)
EGFR gene mutation
 Presence
 Absence
 unknown
13 (8.7)
10 (6.7)
126 (84.6)
Previous EGFR TKI treatment
Response to previous EGFR TKI
53 (35.6)
40 (26.8)
 Previous brain metastasis 
 Previous gamma-knife surgery 
 Previous whole-brain radiotherapy
62 (41.6)
25 (16.8)
34 (22.8)
EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.
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except 26 patients who had initial LC at the diagnosis of lung 
cancer, initial brain magnetic resonance imaging (MRI) was 
performed for 84 patients, and 36 patients without initial brain 
MRI developed LC subsequently. Sixty-two patients (41.6%) 
had a history of previous brain metastasis and were treated 
with gamma-knife surgery or whole-brain irradiation.
Patterns and Clinical Presentation of LC 
The median interval from diagnosis of lung can-
cer to the diagnosis of LC was 11.1 months (range, 0–112) 
(Table 2). Twenty-six patients (17.4%) presented with LC at 
the initial diagnosis of NSCLC, and 64 patients (43.0%) had 
a responsive or stable status of the primary tumor at the time 
of LC diagnosis. The most frequent presenting symptoms of 
LC were symptoms of endocranial hypertension (category 3) 
such as headache, nausea, or vomiting. Most patients (n = 129, 
86.6%) had good ECOG performance status (ECOG PS 0–2).
An elevated opening pressure on lumbar puncture was 
noted in 41.6% of the patients. Among the patients, 21.5%, 
67.1%, and 47.7% had low CSF glucose (normal range, 45–
60 mg/dL), high CSF protein (normal range, 20-40mg/dL), 
and high CSF WBC count (normal range, 0–7/µl), respec-
tively. Gadolinium-enhanced MRI demonstrated leptomen-
ingeal enhancement in 94% of the patients, hydrocephalus 
in 17.4% of the patients, and concurrent brain parenchymal 
metastasis in 65.8% of the patients. Figure 1 illustrates the 
increased incidence of LC in NSCLC over time.
Treatments
Treatment methods after LC diagnosis are summarized 
in Table 3. ITC was administered to 109 patients (73.2%), 
and the median number of ITC administrations was 9 (range, 
1–27); only 15 patients achieved cytologically negative con-
version. In addition to IT chemotherapy, 47 patients (31.5%) 
were treated with whole-brain irradiation, and 36 patients 
TABLE 2.  Patterns and Clinical Presentations of LC (n = 149)
No. of patients 
(%)
Time from diagnosis of lung cancer to LC
 Median months (range) 11.1 (0–112)
Status of primary tumor
 Initially LC
 Partial response or stable disease
 Progressive disease
26 (17.4)
64 (43.0)
59 (39.6)
Clinical onset
 Supratentorial symptoms
 Infratentorial symptoms
 Increase ICP
 Increase ICP plus
 Encephalopathy
 Asymptomatic
15 (10.1)
30 (20.1)
59 (39.6)
29 (19.5)
11 (7.4)
5 (3.4)
ECOG PS 
 ≤2 
 >2
129 (86.6)
20 (13.4)
Initial spinal tapping
 High pressure (Pr > 15mmHg)
 Low glucose (glucose < 45mg/dL)
 High protein (protein > 40mg/dL)
 High WBC (WBC > 7/mm3)
62 (41.6)
32 (21.5)
100 (67.1)
71 (47.7)
Initial MRI enhancement 140 (94.0)
Initial hydrocephalus 26 (17.4)
Concurrent brain parenchymal metastasis 98 (65.8)
LC, leptomeningeal carcinomatosis; ICP, intracranial pressure; ECOG, Eastern 
Cooperative Oncology Group; WBC, white blood cell. 
FIGURE 1.  The frequency of leptomeningeal carcinomatosis 
diagnosis by year. LC, leptomeningeal carcinomatosis.
TABLE 3.  Treatments after Diagnosis of LC
No. of patients (%)
Intrathecal chemotherapy
 + alone
 + radiotherapy
 + systemic therapy
 + radiotherapy + systemic therapy
 Intrathecal chemotherapy (−)
 + radiotherapy
 + systemic therapy
 + radiotherapy + systemic therapy
 Supportive care only
109 (73.2)
44 (29.5)
29 (19.5)
18 (12.1)
18 (12.1)
15 (10.1)
2 (1.3)
3 (2.0)
20 (13.4)
No. of cycles of intrathecal chemotherapy
 Median (range) 9 (1–27)
Cytological response
 Negative conversion 15/109 (13.8)
VP shunt operation 23 (15.4)
Systemic therapy
 EGFR-TKI only
 Cytotoxic chemotherapy only
 EGFR-TKI and cytotoxic chemotherapy
16 (10.7)
17 (11.4)
8 (5.4)
VP, ventriculoperitoneal ; EGFR, epidermal growth factor receptor; TKI, tyrosine 
kinase inhibitor.
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(24.1%) were treated with systemic therapy. Twenty patients 
(13.4%) underwent radiotherapy or systemic therapy without 
ITC, and 20 patients (13.4%) only received supportive care.
Among those patients who were treated with systemic 
therapy, EGFR TKIs were used in 24 patients and cytotoxic 
chemotherapy was used in 25 patients. Among the 25 patients 
who were treated with cytotoxic chemotherapy after LC 
diagnosis, seven patients had platinum-based chemotherapy 
and 18 patients had monotherapy with pemetrexed (n = 10), 
docetaxel (n = 5), or gemcitabine (n = 3). VP shunt opera-
tions were performed in 23 patients (15.4%) for palliation of 
hydrocephalus.
Survival and Prognostic Factors
The median overall survival was 14 weeks (95% CI [12–
16]) (Fig. 2). Certain clinical characteristics, CSF findings, 
and treatment modalities that were useful in predicting 
survival after diagnosis of LC were included in a univariate 
analysis using a log-rank test. Encephalopathy (p = 0.008), 
poor performance status (ECOG PS>2) (p < 0.001), high 
CSF protein level (p = 0.002), low CSF glucose level (p = 
0.002), and high CSF WBC count (p < 0.001) predicted poor 
survival. In contrast, application of intrathecal chemotherapy 
(p < 0.001), EGFR-TKIs (p < 0.001), cytotoxic chemotherapy 
(p < 0.001), whole-brain irradiation (p < 0.001), VP shunt 
operation (p = 0.015), and negative cytologic conversion (p 
= 0.049) predicted favorable survival. The median overall 
survival in patients with an ECOG PS of 2 or less was longer 
than that of patients with an ECOG PS score of 3 or 4 (15 weeks 
versus 6 weeks, p < 0.001; Fig. 3A). Patients who received 
IT chemotherapy demonstrated longer overall survivals 
compared with those who did not receive IT chemotherapy 
(17 weeks versus 8 weeks, p < 0.001; Fig. 3B). Twenty-four 
patients received EGFR-TKIs after a diagnosis of LC, and 
these patients had longer survival periods compared with 
patients who did not receive EGFR-TKIs (38 weeks versus 13 
weeks, p < 0.001; Fig. 3C). Systemic cytotoxic chemotherapy 
and WBRT were also correlated with prolonged survival in 
patients with LC (Fig. 3D and 3E).
We summarized the baseline characteristics and treat-
ment responses of patients who received EGFR-TKIs after 
the diagnosis of LC (Supplemental Digital Content 1, http://
links.lww.com/JTO/A354). Among 24 patients, four had an 
EGFR mutation, and all those patients had partial extra-brain 
responses after EGFR-TKI use. Another 20 patients took 
EGFR-TKIs without undergoing the test for EGFR mutations. 
Among those patients, 11 were nonsmoking women, which is 
a population with a high probability of having EGFR muta-
tions. Nine patients, however, were smokers or men who had 
low probabilities of EGFR mutations. Smoking tended to be 
associated with extra-brain responses after EGFR-TKI use. 
More specifically, among nine smokers, seven patients without 
EGFR mutation showed unresponsive or progressive disease 
after EGFR-TKI treatment, whereas the majority of the 15 
never-smokers showed at least a partial response to EGFR-TKI.
 We performed a multivariate analysis, which included 
factors that were statistically significant in the univariate anal-
ysis for survival. Prognostic factors for poor overall survival, 
which retained statistical significance at the multivariate level 
were poor ECOG PS (p = 0.026; HR 1.361; 95% CI [1.038, 
1.784]), high CSF protein level ( p = 0.027; HR 1.691; 95% 
CI [1.062, 2.691]), and high CSF WBC count ( p = 0.015; HR 
1.690; 95% CI [1.108, 2.580]). The application of intrathecal 
chemotherapy (p < 0.001; HR 0.396; 95% CI [0.248–0.634]), 
EGFR-TKIs (p = 0.018; HR 0.511; 95% CI [0.292l, 0.892]), 
whole brain irradiation ( p = 0.009; HR 0.546; 95% CI [0.347, 
0.858]), and VP shunt operations ( p = 0.013; HR 0.448; 95% 
CI [0.239, 0.842]) were statistically significant factors associ-
ated with a favorable survival (Table 4).
DISCUSSION
To the best of our knowledge, to date, this is the larg-
est study conducted on LC of NSCLC. A notable strength of 
this study was the exclusion of small-cell lung cancer patients 
to only evaluate cases of NSCLC with cytology-positive CSF, 
thereby minimizing the inherent bias resulting from including 
heterogenic tumor types.
The interval between the diagnoses of lung cancer and 
LC varied to a great extent with a range of 0 to 112 months 
(median 11.1 months). Sudo et al.19 reported retrospective 
data on 37 lung cancer patients with LC in 2006. In that study, 
the time from the date of diagnosis of lung cancer to the date 
of diagnosis of LC similarly ranged from 2 days to 8 years 
(median 407 days). Of note in our study, 26 patients (17.4%) 
presented with LC at the time of initial lung cancer diagnosis 
and another 64 patients (43.0%) had a partial response or sta-
ble disease of the primary tumor at the time of LC diagnosis. 
These findings suggest that physicians should be attentive to 
newly diagnosed cancer patients and patients with stable dis-
ease, rather than solely focusing on patients with progressive 
disease or terminal status.
FIGURE 2.  Overall survival after diagnosis of LC.
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FIGURE 3.  Survival curves of patients according to (A) ECOG PS, (B) ITC after diagnosis of LC, (C) EGFR-TKI administration, (D) 
cytotoxic chemotherapy, and (E) WBRT. ECOG PS, Eastern Cooperative Oncology Group performance status; ITC, intrathecal 
chemotherapy; LC, leptomeningeal carcinomatosis; EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitor; WBRT, 
whole-brain radiotherapy.
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The most frequent symptoms related to LC were related 
to endocranial hypertension, such as headache, nausea, and 
vomiting, which is consistent with previous reports.20–22 
Although most patients had neurological symptoms, five 
patients did not present with clinical symptoms at the time of 
diagnosis of LC, but rather LC was suspected based on brain 
imaging. Most patients (n = 140) demonstrated leptomenin-
geal enhancement on the initial brain MRI whereas a small 
number of patients (n = 9) had no leptomeningeal enhance-
ment at the time of LC diagnosis. The findings suggest that 
when patients have typical symptoms of LC without definitive 
findings with brain imaging, further evaluation with a CSF 
exam is warranted.
Although LC is considered to be a fatal disease2,3,7 
with a median overall survival of only 1 to 4 months with 
or without treatment, a subset of LC patients with breast 
cancer or lymphoid malignancies has been shown to achieve 
disease-free survival of a year or more.3,7,23 In our study, 
the median survival was only 14 weeks, and the overall 
survival ranged from 1 week to 29 months. Chamberlain and 
Kormanik22 reported that the median survival was 5 months 
in a prospective study of 32 NSCLC patients with LC and 
good performance status. All 32 patients in that study received 
ITC, and 16 patients also received radiotherapy. The longer 
survival demonstrated in that study might be attributable to 
the exclusion of patients with poor performance status. In 
contrast, Chuang et al.21 reported retrospective data of 34 
lung cancer patients with LC diagnoses from 1992 to 2002 
whose median survival was only 5.1 weeks. A Japanese study 
calculated an average survival of 106 days (range, 10–392) 
which was similar to our results.
The use of EGFR-TKIs in that Japanese study as well 
as our own may in part have contributed to the prolonged 
survival in a specific group of patients.19 In our study, test-
ing for EGFR mutations was performed in only 23 patients 
and among them, 13 patients had EGFR mutations. Although 
we presumed that patients with EGFR mutations who were 
treated with EGFR-TKIs after LC diagnosis would have lon-
ger survival periods, a significance difference was not evident, 
possibly because of the small sample of patients. Patients who 
were clinically suspected but never confirmed to have EGFR 
mutations also took EGFR-TKIs after LC diagnosis, and they 
showed longer survival times than patients who did not take 
EGFR-TKIs.
In our study, the incidence of LC after NSCLC increased 
over time (Fig. 1). With the introduction of many different sal-
vage therapy regimens including docetaxel, pemetrexed, or 
EGFR-TKIs in the treatment of NSCLC, patients are increas-
ingly more likely to be treated aggressively using more than 
two lines of therapy, resulting in a prolonged survival. The 
median survival of patients with activating EGFR mutations 
was double that of patients with wild-type EGFRs, and these 
patients might be more prone to brain or LC metastasis as 
survival time increases.
In our analysis, the univariate analysis identified 
encephalopathy, ECOG PS, CSF findings (protein, glucose 
level, and WBC count), application of ITC, EGFR-TKI use, 
cytotoxic chemotherapy, WBRT, VP shunt operation, and 
cytologic response of CSF as prognostic factors with sig-
nificant impact on survival. In multivariate Cox regression 
analysis, poor ECOG PS, high CSF protein level, and high 
CSF WBC count were therapy-independent predictors of poor 
survival. Moreover, the application of ITC, EGFR-TKI use, 
WBRT, and VP shunt operation were positive prognostic fac-
tors for survival.
Previous studies indicated that cancer type, age (old or 
young), poor PS, time between primary tumor and LC diagno-
sis of 12 months or lesser, serum albumin level, CSF glucose 
level, CSF lactate level, compartmentalization of CSF, coexis-
tent bulky metastatic disease in the CNS, and the presence of 
encephalopathy were negative prognostic factors and that the 
application of systemic chemotherapy was a positive prognos-
tic factor for survival.2,4,20,24 The influence of these prognostic 
factors, however, was not confirmed in multivariate analyses, 
and these reports were limited by including varied types of 
cancer patients with LC. Although several reports that focused 
on only lung cancer patients with LC are available,19,21,25 small 
sample sizes limit the ability to draw conclusions about the 
prognostic factors. Nakamura et al. reported data on 69 lung 
cancer patients with LC.26 They concluded that good PS at 
the time of LC diagnosis was a favorable prognostic factor. In 
addition, EGFR-TKI use and RT for brain and/or spinal cord 
were considered possible treatment options for these patients. 
These findings are similar to our results. Recently, a report of 
50 NSCLC patients with LC concluded that systemic therapy, 
particularly using EGFR-TKIs in addition to ITC, might con-
fer a survival benefit. In our data, certain CSF findings, the 
application of ITC, and VP shunt operations had significant 
impact on survival. However, because of the retrospective 
nature of the current study, a cautious interpretation of the 
findings and future prospective confirmatory studies are war-
ranted. Nevertheless, our study is the largest to date and had 
sufficient statistical power to conduct multiple analyses.
Although ITC is a preferred treatment for LC patients, 
there is no universally accepted data supporting its effective-
ness. Bokstein et al.27 compared patients who were treated 
TABLE 4.  Multivariate Analysis for Survival
Hazard Ratio 95% CI p
Clinical feature
 Encephalopathy
 ECOG PS > 2
1.225
1.361
0.461–3.258
1.038–1.784
0.684
0.026
CSF finding
 High protein
 Low glucose
 High WBC
1.691
1.492
1.690
1.062–2.691
0.914–2.436
1.108–2.580
0.027
0.109
0.015
Treatment after LC
 IT-chemotherapy
 EGFR-TKI
 Cytotoxic chemotherapy
 WBRT
 VPS
 Cytologic negative conversion
0.396
0.511
0.644
0.546
0.448
0.523
0.248–0.634
0.292–0.892
0.368–1.125
0.347–0.858
0.239–0.842
0.263–1.039
<0.001
0.018
0.122
0.009
0.013
0.064
CI, confidence interval.
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with systemic chemotherapy and radiotherapy with ITC ver-
sus without ITC and found that there was no significant dif-
ference in overall survival. On the one hand, Boogerd et al.28 
performed a randomized trial in breast cancer patients with 
LC and similarly did not find a survival benefit in using intra-
CSF chemotherapy. On the other hand, Bruna et al.20 reported 
that intrathecal treatment was independently associated with a 
longer survival in a similar subset of patients. 
Given the heterogeneous modalities of treatment that 
were used in this retrospective study, the precise roles of those 
various treatments remain controversial and need to be vali-
dated in a prospective study. However, in contrast to many 
previous reports4,24 that suggested that systemic chemotherapy 
prolonged survival in LC, our results indicated that only ITC, 
EGFR-TKIs, WBRT, and VP shunt operations were associated 
with prolonged survival. Such discrepancies may be attribut-
able to the heterogeneous types of cancer included in different 
studies.
In conclusion, our large sample size of patients with 
NSCLC and LC demonstrated that good ECOG PS, low 
initial CSF protein level, and low initial CSF WBC count 
were favorable prognostic factors. Active treatments with ITC, 
EGFR-TKIs, WBRT, and VP shunt operations additionally 
prolonged survival. Because our data only included patients of 
Korean descent and the population in this series was relatively 
young, predominantly nonsmoker, female, and exclusively 
had adenocarcinoma histology, our results cannot be directly 
applied to Western patients with different demographics 
and characteristics from ours. Considering the fatal clinical 
courses of NSCLC patients with LC, more active treatment 
strategies including ITC, EGFR-TKI use, WBRT, and VP 
shunt operation may be associated with improvement of 
clinical outcomes in the subset of NSCLC patients with LC.
REFERENCES
 1. Gleissner B, Chamberlain MC. Neoplastic meningitis. Lancet Neurol 
2006;5:443–452.
 2. Chamberlain MC. Neoplastic meningitis. J Clin Oncol 2005;23:3605–3613.
 3. DeAngelis LM, Boutros D. Leptomeningeal metastasis. Cancer Invest 
2005;23:145–154.
 4. Herrlinger U, Förschler H, Küker W, et al. Leptomeningeal metas-
tasis: survival and prognostic factors in 155 patients. J Neurol Sci 
2004;223:167–178.
 5. Chamberlain MC, Junck L. Defining patients at risk for neoplastic men-
ingitis: what parameters can be used to determine who should be treated? 
Expert Rev Neurother 2004;4(4 Suppl):3S–10S.
 6. Kaplan JG, DeSouza TG, Farkash A, et al. Leptomeningeal metastases: 
comparison of clinical features and laboratory data of solid tumors, lym-
phomas and leukemias. J Neurooncol 1990;9:225–229.
 7. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of lep-
tomeningeal metastases from solid tumors: experience with 90 patients. 
Cancer 1982;49:759–772.
 8. Chamberlain MC. Anticancer therapies and CNS relapse: overcoming 
blood-brain and blood-cerebrospinal fluid barrier impermeability. Expert 
Rev Neurother 2010;10:547–561.
 9. Pentheroudakis G, Pavlidis N. Management of leptomeningeal malig-
nancy. Expert Opin Pharmacother 2005;6:1115–1125.
 10. Taillibert S, Hildebrand J. Treatment of central nervous system metas-
tases: parenchymal, epidural, and leptomeningeal. Curr Opin Oncol 
2006;18:637–643.
 11. Masuda T, Hattori N, Hamada A, et al. Erlotinib efficacy and cerebrospi-
nal fluid concentration in patients with lung adenocarcinoma developing 
leptomeningeal metastases during gefitinib therapy. Cancer Chemother 
Pharmacol 2011;67:1465–1469.
 12. Fujikura Y, Morishima Y, Ota K, et al. [Satisfactory outcome with erlo-
tinib after failure with gefitinib in a patient with meningeal carcinoma-
tosis secondary to non-small cell lung cancer]. Nihon Kokyuki Gakkai 
Zasshi 2010;48:391–396.
 13. Yi HG, Kim HJ, Kim YJ, et al. Epidermal growth factor receptor (EGFR) 
tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metas-
tasis from non-small cell lung cancer patients with sensitive EGFR muta-
tion or other predictive factors of good response for EGFR TKI. Lung 
Cancer 2009;65:80–84.
 14. Hitchins RN, Bell DR, Woods RL, Levi JA. A prospective randomized 
trial of single-agent versus combination chemotherapy in meningeal car-
cinomatosis. J Clin Oncol 1987;5:1655–1662.
 15. Giannone L, Greco FA, Hainsworth JD. Combination intraventricular 
chemotherapy for meningeal neoplasia. J Clin Oncol 1986;4:68–73.
 16. Kim DY, Lee KW, Yun T, et al. Comparison of intrathecal chemotherapy 
for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone 
versus methotrexate in combination with cytosine arabinoside and hydro-
cortisone. Jpn J Clin Oncol 2003;33:608–612.
 17. Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled 
trial comparing intrathecal sustained-release cytarabine (DepoCyt) to 
intrathecal methotrexate in patients with neoplastic meningitis from solid 
tumors. Clin Cancer Res 1999;5:3394–3402.
 18. Grossman SA, Finkelstein DM, Ruckdeschel JC, Trump DL, Moynihan 
T, Ettinger DS. Randomized prospective comparison of intraventricular 
methotrexate and thiotepa in patients with previously untreated neo-
plastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 
1993;11:561–569.
 19. Sudo J, Honmura Y, Kurimoto F, Komagata H, Sakai H, Yoneda S. 
[Meningeal carcinomatosis in patients with lung cancer]. Nihon Kokyuki 
Gakkai Zasshi 2006;44:795–799.
 20. Bruna J, González L, Miró J, Velasco R, Gil M, Tortosa A; Neuro-
Oncology Unit of the Institute of Biomedical Investigation of Bellvitge. 
Leptomeningeal carcinomatosis: prognostic implications of clinical and 
cerebrospinal fluid features. Cancer 2009;115:381–389.
 21. Chuang TY, Yu CJ, Shih JY, Yang PC, Kuo SH. Cytologically proven men-
ingeal carcinomatosis in patients with lung cancer: clinical observation of 
34 cases. J Formos Med Assoc 2008;107:851–856.
 22. Chamberlain MC, Kormanik P. Carcinoma meningitis secondary to 
non-small cell lung cancer: combined modality therapy. Arch Neurol 
1998;55:506–512.
 23. Chamberlain MC. Leptomeningeal metastasis. Curr Opin Neurol 
2009;22:665–674.
 24. Oechsle K, Lange-Brock V, Kruell A, Bokemeyer C, de Wit M. Prognostic 
factors and treatment options in patients with leptomeningeal metastases 
of different primary tumors: a retrospective analysis. J Cancer Res Clin 
Oncol 2010;136:1729–1735.
 25. Park JH, Kim YJ, Lee JO, et al. Clinical outcomes of leptomeningeal 
metastasis in patients with non-small cell lung cancer in the modern che-
motherapy era. Lung Cancer 2012;76:387–392.
 26. Nakamura Y, Takahashi T, Kenmotsu H, et al. Prognostic factors of 
lung cancer patients with carcinomatous meningitis. ESMO (Meeting 
Abstracts) 2010.
 27. Bokstein F, Lossos A, Siegal T. Leptomeningeal metastases from solid 
tumors: a comparison of two prospective series treated with and without 
intra-cerebrospinal fluid chemotherapy. Cancer 1998;82:1756–1763.
 28. Boogerd W, van den Bent MJ, Koehler PJ, et al. The relevance of intraven-
tricular chemotherapy for leptomeningeal metastasis in breast cancer: a 
randomised study. Eur J Cancer 2004;40:2726–2733.
